PT2753646T - Anticorpos anti-cd40, suas utilizações e métodos - Google Patents
Anticorpos anti-cd40, suas utilizações e métodos Download PDFInfo
- Publication number
- PT2753646T PT2753646T PT127617868T PT12761786T PT2753646T PT 2753646 T PT2753646 T PT 2753646T PT 127617868 T PT127617868 T PT 127617868T PT 12761786 T PT12761786 T PT 12761786T PT 2753646 T PT2753646 T PT 2753646T
- Authority
- PT
- Portugal
- Prior art keywords
- seq
- antibody
- cells
- antigen
- binding fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1115280.8A GB201115280D0 (en) | 2011-09-05 | 2011-09-05 | Antibodies, uses and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2753646T true PT2753646T (pt) | 2018-02-07 |
Family
ID=44882205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127617868T PT2753646T (pt) | 2011-09-05 | 2012-09-05 | Anticorpos anti-cd40, suas utilizações e métodos |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9676862B2 (enExample) |
| EP (2) | EP2753646B1 (enExample) |
| JP (1) | JP6324891B2 (enExample) |
| KR (1) | KR102029946B1 (enExample) |
| CN (1) | CN103930442B (enExample) |
| AU (1) | AU2012306071B2 (enExample) |
| CA (1) | CA2860406C (enExample) |
| CY (1) | CY1119925T1 (enExample) |
| DK (2) | DK3323834T3 (enExample) |
| ES (2) | ES2658157T3 (enExample) |
| GB (1) | GB201115280D0 (enExample) |
| HR (1) | HRP20180269T1 (enExample) |
| HU (1) | HUE036538T2 (enExample) |
| LT (1) | LT2753646T (enExample) |
| NO (1) | NO2753646T3 (enExample) |
| PL (1) | PL2753646T3 (enExample) |
| PT (1) | PT2753646T (enExample) |
| RS (1) | RS56868B1 (enExample) |
| RU (1) | RU2649055C2 (enExample) |
| SI (1) | SI2753646T1 (enExample) |
| SM (1) | SMT201800144T1 (enExample) |
| WO (1) | WO2013034904A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| PT2953634T (pt) | 2013-02-07 | 2021-09-02 | Massachusetts Gen Hospital | Métodos de expansão ou depleção das células t reguladoras |
| MX382549B (es) * | 2014-08-12 | 2025-03-13 | Alligator Bioscience Ab | Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. |
| EP3750918A1 (en) | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| AU2016263198C1 (en) * | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| EP3340999A4 (en) | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES |
| US20190048089A1 (en) * | 2015-09-30 | 2019-02-14 | Janssen Biotech, Inc. | Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| EP3455262A4 (en) | 2016-05-13 | 2020-04-08 | The General Hospital Corporation | ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES |
| AR108611A1 (es) * | 2016-05-27 | 2018-09-05 | Abbvie Biotherapeutics Inc | Anticuerpos anti-cd40 y sus usos |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| CN109863170B (zh) | 2016-08-12 | 2024-08-16 | 詹森生物科技公司 | 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子 |
| CN109843916B (zh) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法 |
| EP3534952A4 (en) | 2016-11-04 | 2020-06-10 | Memorial Sloan-Kettering Cancer Center | BI-SPECIFIC ACTIVATORS FOR ANTI-TUMOR THERAPY |
| GB201619652D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel polypeptides |
| WO2018115003A2 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| EP3589324A1 (en) * | 2017-03-03 | 2020-01-08 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| AU2018278051A1 (en) | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| SG11202002366VA (en) | 2017-09-19 | 2020-04-29 | Mab Discovery Gmbh | Agonistic cd40 antibodies |
| KR20200074993A (ko) | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR20210005082A (ko) | 2018-04-20 | 2021-01-13 | 리브젠 바이오파마 코., 엘티디. | 항-cd40 항체 및 이의 용도 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| JP7626698B2 (ja) * | 2018-09-28 | 2025-02-04 | リビジェン バイオファーマ ホールディングス リミテッド | 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途 |
| EP3856790A4 (en) * | 2018-09-28 | 2022-09-28 | Lyvgen Biopharma Holdings Limited | ANTI-CD40 BINDING MOLECULES WITH ENGINEERED FC DOMAINS AND THEIR THERAPEUTIC USES |
| CN113302205B (zh) | 2018-11-15 | 2024-12-06 | 综合医院公司 | 激动性肿瘤坏死因子受体超家族多肽 |
| WO2020108621A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| BR112021009835A2 (pt) | 2018-11-30 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| AU2020284706A1 (en) | 2019-05-28 | 2021-12-16 | Alligator Bioscience Ab | Method of providing safe administration of an anti-CD40 antibody |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20210214454A1 (en) | 2020-01-10 | 2021-07-15 | Symphogen A/S | Anti-cd40 antibodies and compositions |
| GB202004677D0 (en) * | 2020-03-31 | 2020-05-13 | Alligator Bioscience Ab | Methods and compositions |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| CN117836310A (zh) * | 2021-04-15 | 2024-04-05 | 万可真株式会社 | 细胞穿透肽、抗癌肽和包括其的用于预防或治疗癌症的药物组合物 |
| BR112023026111A2 (pt) * | 2021-06-28 | 2024-03-05 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US20240141016A1 (en) * | 2021-11-05 | 2024-05-02 | Navicure Biopharmaceuticals Limited | Immunogenic fusion proteins against infectious animal diseases |
| WO2023079101A2 (en) | 2021-11-05 | 2023-05-11 | Alligator Bioscience Ab | Novel polypeptides |
| CA3257929A1 (en) | 2022-05-31 | 2025-04-22 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Anti-CD40 antibodies, bispecific anti-PD-L1×CD40 antibodies, and their use |
| CA3260666A1 (en) * | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Combination therapies |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| EP4643877A1 (en) * | 2022-12-28 | 2025-11-05 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Composition of cd40-binding molecule and pharmaceutical use thereof |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025093035A1 (en) * | 2023-11-03 | 2025-05-08 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5149796A (en) | 1989-08-31 | 1992-09-22 | City Of Hope | Chimeric DNA-RNA catalytic sequences |
| US5643872A (en) | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US6008058A (en) | 1993-06-18 | 1999-12-28 | University Of Louisville | Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis |
| WO1996006641A1 (en) | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO2000009153A1 (en) * | 1997-10-29 | 2000-02-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US6958213B2 (en) * | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| WO2002048351A2 (en) | 2000-12-12 | 2002-06-20 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| CA2658221C (en) * | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| EP1504098B2 (en) | 2002-05-17 | 2011-02-09 | Alligator Bioscience AB | A method for in vitro molecular evolution of protein function |
| KR20070026522A (ko) * | 2004-04-27 | 2007-03-08 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법 |
| CA2609269C (en) * | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| WO2009094391A1 (en) | 2008-01-23 | 2009-07-30 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
-
2011
- 2011-09-05 GB GBGB1115280.8A patent/GB201115280D0/en not_active Ceased
-
2012
- 2012-09-05 RS RS20180200A patent/RS56868B1/sr unknown
- 2012-09-05 PL PL12761786T patent/PL2753646T3/pl unknown
- 2012-09-05 WO PCT/GB2012/052179 patent/WO2013034904A1/en not_active Ceased
- 2012-09-05 DK DK17195987.7T patent/DK3323834T3/da active
- 2012-09-05 US US14/342,141 patent/US9676862B2/en active Active
- 2012-09-05 JP JP2014527743A patent/JP6324891B2/ja active Active
- 2012-09-05 SI SI201231140T patent/SI2753646T1/en unknown
- 2012-09-05 HR HRP20180269TT patent/HRP20180269T1/hr unknown
- 2012-09-05 EP EP12761786.8A patent/EP2753646B1/en active Active
- 2012-09-05 CA CA2860406A patent/CA2860406C/en active Active
- 2012-09-05 RU RU2014113304A patent/RU2649055C2/ru active
- 2012-09-05 PT PT127617868T patent/PT2753646T/pt unknown
- 2012-09-05 SM SM20180144T patent/SMT201800144T1/it unknown
- 2012-09-05 ES ES12761786.8T patent/ES2658157T3/es active Active
- 2012-09-05 LT LTEP12761786.8T patent/LT2753646T/lt unknown
- 2012-09-05 DK DK12761786.8T patent/DK2753646T3/en active
- 2012-09-05 NO NO12761786A patent/NO2753646T3/no unknown
- 2012-09-05 KR KR1020147008695A patent/KR102029946B1/ko active Active
- 2012-09-05 AU AU2012306071A patent/AU2012306071B2/en active Active
- 2012-09-05 HU HUE12761786A patent/HUE036538T2/hu unknown
- 2012-09-05 EP EP17195987.7A patent/EP3323834B1/en active Active
- 2012-09-05 ES ES17195987T patent/ES2967316T3/es active Active
- 2012-09-05 CN CN201280054090.1A patent/CN103930442B/zh active Active
-
2017
- 2017-05-08 US US15/588,919 patent/US10640567B2/en active Active
-
2018
- 2018-02-09 CY CY20181100161T patent/CY1119925T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2753646T (pt) | Anticorpos anti-cd40, suas utilizações e métodos | |
| JP6970991B2 (ja) | トランスポザーゼポリペプチド及びその使用 | |
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| EP3858856A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof in cell therapy | |
| CN114245807A (zh) | Flt3l-fc融合蛋白和使用方法 | |
| JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
| CN113164589A (zh) | 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途 | |
| CN110461315A (zh) | 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征 | |
| JP2017534280A (ja) | 腫瘍を標的にするがｔ細胞を標的にしないサバイビン特異的ｔ細胞受容体 | |
| KR20220093103A (ko) | 항종양용해 바이러스 항원 항체 및 이의 사용 방법 | |
| CN113454115A (zh) | 靶向唾液酸化路易斯a的嵌合抗原受体及其用途 | |
| US20220265847A1 (en) | Methods and compositions for treating non-small cell lung cancer | |
| TW201206474A (en) | Treating breast cancer with anti-IL-19 antibody | |
| TW201206468A (en) | Treating oral cancer with anti-IL-20 antibody | |
| CN116410315A (zh) | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 | |
| JP7810446B2 (ja) | Ｈｅｒｖ－ｋ抗体治療薬 | |
| CN118440200B (zh) | 靶向ror1的抗体及其应用 | |
| TW201806970A (zh) | 嵌合抗原受體、及其利用 | |
| WO2024012495A1 (zh) | 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用 | |
| CN114685683A (zh) | 靶向gd2的car-t细胞及其制备和应用 | |
| CN110251666A (zh) | 一种用于癌症靶向或免疫治疗的组合物及其应用 | |
| WO2025242073A1 (zh) | 双靶点嵌合抗原受体、免疫效应细胞及应用 | |
| WO2026026529A1 (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| CN121511096A (zh) | 药物组合物及其应用 | |
| HK40071848A (en) | Flt3l-fc fusion proteins and methods of use |